Home › Trials › NCT07159750

Real-world use of anti-CGRP medicines for preventing migraine

Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

Observational Hospital Universitari Vall d'Hebron Research Institute · NCT07159750

This project will follow people with episodic or chronic migraine who start anti-CGRP medicines to see if the treatments reduce migraine frequency and side effects over two years.

Quick facts

Study typeObservational
Enrollment700 (estimated)
Ages18 Years and up
SexAll
SponsorHospital Universitari Vall d'Hebron Research Institute Academic / other
Drugs / interventionserenumab, galcanezumab, fremanezumab, eptinezumab
Locations26 sites (Miami, Florida and 25 other locations)
Trial IDNCT07159750 on ClinicalTrials.gov

What this trial studies

This is a 2-year multicenter observational project that follows patients prescribed anti-CGRP monoclonal antibodies or gepants under routine care. Participants undergo a baseline assessment when treatment starts and return every six months to record treatment effectiveness, side effects, patient-reported outcome measures, and ongoing eligibility for the medication. Inclusion depends on a migraine diagnosis (ICHD-III) and meeting local prescriber and reimbursement criteria, with consent obtained before enrollment. No experimental interventions are assigned — treatments are given per clinicians' decisions and the study collects real-world data to compare outcomes across different anti-CGRP options.

Who should consider this trial

Good fit: Adults diagnosed with episodic or chronic migraine who are prescribed an anti-CGRP monoclonal antibody (erenumab, galcanezumab, fremanezumab, eptinezumab) or a gepant (rimegepant, atogepant) and meet local reimbursement and consent requirements.

Not a fit: Patients whose headaches are not migraine, who have active severe psychiatric or cognitive impairment affecting consent, or who are not prescribed or reimbursed for anti-CGRP therapy locally would not benefit from or be eligible for this project.

Why it matters

Potential benefit: If successful, the results could help doctors and patients choose which anti-CGRP medicine is likely to work best or be better tolerated in routine practice.

How similar studies have performed: Randomized trials and accumulating real-world studies of anti-CGRP monoclonal antibodies and gepants have shown reductions in migraine frequency and acceptable tolerability, so this study extends that evidence into routine care settings.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Migraine diagnosis according to ICHD-III.
* Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations.
* Signature of informed consent.

Exclusion Criteria:

* Presence of headache different from migraine.
* Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.

Where this trial is running

Miami, Florida and 25 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions MigraineEpisodic MigraineChronic Migraine, HeadachePreventionChronic Migrainegalcanezumaberenumabfremanezumab
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.